Amarin Corporation's (AMRN) flagship product, Vascepa, is not an antiviral, steroid, antibody, or vaccine, but investors need to be aware of its potential to be a COVID-19 therapeutic. Vascepa (icosapent ethyl) is an FDA approved as an adjunct to maximally tolerated statin therapy to diminish the risk of cardiovascular events in certain adults with high triglyceride levels of 150 mg/dc or higher and other cardiovascular risk factors and to reduce severely elevated levels of triglycerides of 500 mg/dl or higher. Vascepa is expected to help reduce the risk of heart attack, stroke, and